menu
    • menu

    Company profile for Palatin Technologies

    NEW Drugs in Dev: 7
    Minakem delivers API, HPAPI, steroids & CDMO services for generics with FDA/GMP certification, regulatory know-how & proven success.

    Virtual Booth

    Contact Supplier

    Boai NKY Pharmaceuticals Ltd. is one of the largest global PVP suppliers.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    Contact Supplier

    Nanjing Well is focused on R&D, production & sales of Pharmaceutical Excipients & Synthetic Lubricating base oils.

    Virtual Booth

    Contact Supplier

    Ever Pharma, highly specialized CDMO in producing complex injectables including high potency & controlled substances, suspensions, etc.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Palatin Technologies, Inc. (NYSE American: PTN) is a specialized biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems. Our product candidates are targeted, receptor-specific therapeutics for the treatment of diseases with significant unmet medical need and commercial potential. Vyleesi™, the trade name for Br...
    Palatin Technologies, Inc. (NYSE American: PTN) is a specialized biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems. Our product candidates are targeted, receptor-specific therapeutics for the treatment of diseases with significant unmet medical need and commercial potential. Vyleesi™, the trade name for Bremelanotide, for the treatment of hypoactive sexual desire disorder (HSDD) is our lead product. A New Drug Application for approval of Vyleesi was approved by the Food and Drug Administration (FDA) in June 2019.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Palatin TechnologiesUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    4-B Cedar Brook Drive Cedar Brook Corporate Center Cranbury, NJ 08512
    Telephone
    Telephone
    1-609-495-2200
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://palatin.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    PEGS Boston Summit

    PEGS Boston Summit

    Not Confirmed

    envelop Contact Supplier

    PEGS Boston Summit

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Palatin To Begin Trading On Nasdaq Stock Exchange
    Palatin To Begin Trading On Nasdaq Stock Exchange

    19 May 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/palatin-to-begin-trading-on-nasdaq-stock-exchange-302774038.html

    PR NEWSWIRE
    19 May 2026
    Share Share
    Palatin Reports Fiscal Q3 2026 Results, Business Update
    Palatin Reports Fiscal Q3 2026 Results, Business Update

    13 May 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/palatin-reports-fiscal-third-quarter-2026-financial-results-and-provides-business-update-302770261.html

    PR NEWSWIRE
    13 May 2026
    Share Share
    Palatin Reveals Q2 Fy2026 Financials And Corporate Progress
    Palatin Reveals Q2 Fy2026 Financials And Corporate Progress

    17 Feb 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/palatin-reports-second-quarter-fiscal-year-2026-financial-results-and-provides-corporate-update-302688156.html

    PR NEWSWIRE
    17 Feb 2026
    Share Share
    Palatin Reveals Q1 Fy2026 Financials And Corporate Progress
    Palatin Reveals Q1 Fy2026 Financials And Corporate Progress

    13 Nov 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/palatin-reports-first-quarter-fiscal-year-2026-financial-results-and-provides-corporate-update-302614162.html

    PR NEWSWIRE
    13 Nov 2025
    Share Share
    Palatin Technologies Closes $18.2M Upsized Offering
    Palatin Technologies Closes $18.2M Upsized Offering

    12 Nov 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/palatin-technologies-announces-closing-of-upsized-18-2-million-public-offering-with-the-full-exercise-of-the-underwriters-over-allotment-option-302613372.html

    PR NEWSWIRE
    12 Nov 2025
    Share Share
    Palatin Pharma Sets $15.8M Public Offering Price
    Palatin Pharma Sets $15.8M Public Offering Price

    06 Nov 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/palatin-technologies-announces-pricing-of-upsized-15-8-million-public-offering-302606870.html

    PR NEWSWIRE
    06 Nov 2025
    Share Share

    Inspections and registrations

    Upload your audits for free, ask us

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search